Dr. Mark Levandovsky's Credentials

Accepting New Patients

Yes, this doctor is accepting new patients

Biography

As the founder and medical director of his Preventive Medicine and Cancer Care practice, Dr. Levandovsky provides personalized care to health conscious individuals - as well as active cancer patients and cancer survivors. He focuses on on a integrative care delivery, genetic and molecular risk assessments, preventive strategies, education, nutrition and psycho-oncology. Dr. Levandovsky received his medical degree from University of California Irvine School of Medicine and has been in practice for 17 years. He began his medical career at the University of California Davis Medical Center in Sacramento and has helped cancer patients across the country, including at Weill Cornell-New York Presbyterian Hospital in New York City and the Alaska Cancer Treatment and Research Center in Anchorage, Alaska. Most recently, Dr. Levandovsky served as the Head of Breast and Urologic Oncology at St. Mary's Medical Cancer Center in Grand Junction, Colorado.

Languages

• Spanish
• Russian
• English

Education

• University Of California, Davis School Of Medicine (Grad. 2004)

Other Specialties

• Family Doctor / General Practitioner
• Oncologist / Hematologist

Areas of Expertise

• Kidney cancer
• Liver cancer
• Ovarian cancer
• Pancreatic cancer
• Lung cancer
• Male breast cancer
• Mouth cancer
• Anal cancer
• Hurthle cell cancer
• Oral cancer screening
• Gallbladder cancer
• Lung cancer screening

Awards & Recognitions

• Dean’s Research Program Award
• NIH Research Grant
• Lewis A. Kingsley and Presidential Scholar
• American Society of Hematology
• UC Irvine College of Medicine Research Award
• Margaret Erdt Scholar
• American Society of Clinical Oncology

Publications & Research

• Levandovsky et al, J Hematol Oncol. Dec. 2008; 1: 23: Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS)
• Levandovsky et al (PI, NIH-sponsored, investigator-initiated pilot clinical trial). Markers of Thrombosis, Hemostasis, and Angiogenesis as predictors of outcome in Advanced Prostate Cancer.
• Levandovsky et al (submitted for review): Case Report: Two Cases of Port Site Recurrences after Laparoscopic Nephrectomy for Collecting Duct Carcinoma
• Levandovsky et al (submitted for review): Review of Incidence and Risk Factors for Venous Thromboembolism in Prostate Cancer
• Arnason, Levandovsky et al, Thrombosis Research, Apr. 2010; 125, S165. OC-15 Hemostatic activation, fibrinolysis and angiogenesis are increased in patients with advanced prostate cancer (PC) and decrease in response to hormonal therapy.